Dr. Hoimes on EV-103 Results in Urothelial Cancer

Video

Christopher J. Hoimes, DO, discusses the results of the EV-103 trial in patients with locally advanced or metastatic urothelial cancer.

Christopher J. Hoimes, DO, assistant professor, Department of Medicine Division of Hematology and Oncology, School of Medicine, member, GU Malignancies Program, Case Comprehensive Cancer Center, Case Western Reserve University, discusses the results of the EV-103 trial in patients with locally advanced or metastatic urothelial cancer.

The phase Ib/II EV-103 trial, a single-arm, multi-site study, examined enfortumab vedotin with pembrolizumab (Keytruda) in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, explains Hoimes. Patients were put in a dose-escalation cohort as well as in a dose-expansion cohort.

The dose-escalation cohort identified no dose-limiting toxicities and a randomized recommended phase II dose of 1.25 mg/kg of enfortumab vedotin given on days 1 and 8, concludes Hoimes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,